Morgan Stanley analyst Robert Davies raised the firm’s price target on Fresenius Medical (FMS) to EUR 46 from EUR 43 and keeps an Underweight rating on the shares.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FMS:
- Fresenius Medical Care Launches EUR 1 Billion Share Buyback Program
- Fresenius Medical announces first tranche of share buyback program
- Fresenius Medical price target lowered to EUR 48 from EUR 50 at Deutsche Bank
- Hold Rating Maintained for Fresenius Medical Care Amidst Flat US Growth and Downward Financial Adjustments
- Fresenius Medical Care Reports Modest Growth in 2025 Earnings